Management Advisory Board (MAB)
James Barry, Ph.D.
Former SVP, Corporate Research and Advanced Technology Development, Boston Scientific
Dr. Barry was most recently SVP, Corporate Research and Advanced Technology Development at Boston Scientific and also represented the company on the Boards of emerging technology companies. He was the initiator and champion of the company's drug eluting stent program which resulted in the TAXUS™ coronary stent, developed under his leadership, that became the most successful medical device ever launched ($3Bn Annual sales). Dr. Barry is the author of multiple articles in peer reviewed publications, including the journals of Controlled Release, Biomaterials and several clinical journals in the cardiovascular field and holds in excess of 35 national and international patents. Currently, he serves as a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center (appointed by the Governor), Advisory Board of the Massachusetts Medical Device Center at UMass Lowell, the Office of Commercial Ventures and Intellectual Property at UMass Lowell, and the Biomedical Engineering Board at Yale University.
Bruce KenKnight, Ph.D
Chief Executive Officer, Valtech Cardio
Dr. KenKnight is Chief Executive Officer of Valtech Cardio and has more than 25 years of experience in medical device R&D, most recently as VP of Research and Business Development in the CRM division of Boston Scientific, where he participated in over 50 deals. Previously, Bruce was Director of Research and Emerging Technologies for Guidant while cardiac resynchronization therapy was developed and commercialized, which now generates in excess of $3 billion in annual worldwide revenue. He is an inventor of more than 100 patents and has authored 150 scientific publications. In 2006, he received the Albert Einstein Award for Outstanding Achievement in Life Sciences. Bruce earned a B.S. in Mechanical Engineering and a Masters and Ph.D. in Biomedical Engineering from the University of Minnesota.
Chief Executive Officer, T2Biosystems
John McDonough is currently CEO of T2Biosystems. Prior to joining T2, John was President of Cytyc Corporation and had responsibility corporate strategy, acquisitions, product development and operations. John led over $1B in acquisitions that drove the company from $300 million in revenue to $750 million in 4 years. In 2007, John then led the efforts that resulted in Cytyc's acquisition by Hologic, for over $6Bn, almost a 6 times increase in market cap over a 4 year period. Before Cytyc, he served as CEO at SoundBite Communications, which went public. Previously, he was COO of Direct Hit Technologies, acquired for over $500 million, and CEO of Workgroup Technology, a product development management solutions company. Mr. McDonough also spent 10 years with Easel Corporation where he held the role of CFO, COO and then CEO of a start-up company that grew into a publicly held company in 1990 and was acquired in 1995.
Eric Prystowsky, M.D.
Director, EP Laboratory, St. Vincent Hospital Indianapolis, IN
Dr. Eric Prystowsky is internationally recognized as an expert in atrial fibrillation. He has co-authored two textbooks and authored over 640 articles and abstracts concerning cardiac arrhythmias. He currently serves as Editor-in-Chief of the Journal of Cardiovascular Electrophysiology. Dr. Prystowsky serves on the Board of Directors of CardioNet, Inc (NASDAQ: BEAT) and Stereotaxis, Inc (NASDAQ: STXS). He is the past Chairman of the ABIM test writing committee for the Electrophysiology Boards, past Chairman of the American Heart Association's Committee on Electrocardiography and Electrophysiology, and past President of the Heart Rhythm Society.
Topera, Chairman of the Board of Directors.
Mr. Taylor was most recently President & CEO of Photothera, Inc., a medical device company whose platform technology seeks to employ penetrating near-infrared laser energy to treat a broad range of diseases. Mr. Taylor previously served as VP and General Manager for the Kyphon Business of Medtronic, Inc. Prior to Medtronic's acquisition of Kyphon, Mr. Taylor served as Kyphon's COO from 2006, and as CFO from 2004 through 2006. Prior to his Kyphon tenure, Mr. Taylor gained in-depth experience across the medical device industry while serving as CFO for ReSound Corporation, a hearing healthcare company, and in executive positions with Allergan, Inc. and American Hospital Supply Corporation. Mr. Taylor holds a B.S. in Corporate Finance from San Diego State University and an M.B.A. from USC.
President and CEO of TYRX, Inc.
Mr. White is President and CEO of TYRX, Inc. and has over 20 years of experience in the medical technology industry in positions of increasing responsibility, most recently as President of Medtronic Kyphon following the $3.9 billion acquisition of the business. During his time with Medtronic, Mr. White also served as President of Physio Control and was responsible for commercial operations for Medtronic Cardiac Rhythm Disease Management as Vice President of U.S. Sales and Global Marketing. Mr. White holds an M.B.A. from Cornell University and a B.S. in Aerospace Engineering from the University of Missouri-Rolla.